Oligo Analytics
Impurities, Sequence Fidelity, and Structural Variants in Nucleic Acid Therapeutics
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-23May 26, 2026
Greener TIDES
Greener Pathways for Peptide and Oligonucleotide Manufacturing
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-15May 14, 2026
Scaling Oligos
Scaling Oligonucleotide Manufacturing: When Chemistry Becomes the Constraint
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-08May 7, 2026
Oligo Delivery
Expanding the Reach of Oligonucleotide Drugs Through Delivery Innovation
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-06May 5, 2026
Conjugate Payloads
Beyond Cytotoxins: Expanding the Payload Landscape for Antibody-Based Conjugates
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-03May 1, 2026
CRISPR
Integrated Capabilities Enable Faster Development of Effective CRISPR Therapies
Jessica Madigan; Amanda Haas
BIOVECTRA
PAO-11-25-CL-03Nov 21, 2025
LNPs
Expanding LNP Applications Beyond mRNA Vaccines
Jan Bekker; Phillip Elliott, Ph.D.; Jason Arcediano
BioCina
PAO-10-25-CL-07Nov 17, 2025
Gene Tools
Unlocking New Possibilities in Research, Therapeutics, and Beyond with Morpholino Antisense Oligos
David Alvaro, Ph.D.; Jon Moulton, Ph.D.
Pharma's Almanac
PAO-01-23-CL-05Feb 1, 2023
Column: New Drug Watch
Potential Applications for Antisense Oligonucleotide Therapies Continue to Expand
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-10-022-NI-06Oct 11, 2022
Expanded Capacity
WuXi STA Opens Oligonucleotide Large-Scale Manufacturing Facility
WuXi STA
PR-M01-20-NI-010Jan 7, 2020
Oligonucleotides
Designing Effective Facilities to Meet the Growing Demand for Oligonucleotide Drugs
Bill Jarvis; Brendan Nichols
CRB USA
PAP-Q4-18-CL-002Oct 26, 2018
Strategic Partnership
New Collaboration Targets the Development of Oligonucleotides
Nigel Walker
Nice Insight
PAO-M12-17-NI-002Dec 1, 2017